---
title: Uric Acid and the Endothelium in CKD
nct_id: NCT01228903
overall_status: COMPLETED
phase: NA
sponsor: University of Colorado, Denver
study_type: INTERVENTIONAL
primary_condition: Kidney Disease
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01228903.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01228903"
ct_last_update_post_date: 2017-06-28
last_seen_at: "2026-05-12T06:16:13.584Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Uric Acid and the Endothelium in CKD

**Official Title:** Is Uric Acid a Mediator of Endothelial Dysfunction in Patients With Chronic Kidney Disease?

**NCT ID:** [NCT01228903](https://clinicaltrials.gov/study/NCT01228903)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 80
- **Lead Sponsor:** University of Colorado, Denver
- **Collaborators:** National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Conditions:** Kidney Disease
- **Start Date:** 2010-10
- **Completion Date:** 2016-09
- **CT.gov Last Update:** 2017-06-28

## Brief Summary

This study will test the hypothesis that uric acid impairs the function of vessels in patients with kidney disease

## Detailed Description

The purpose of the study is to understand the effect of lowering serum uric acid levels on vascular function in individuals with chronic kidney disease by comparing the effects of:

1\) Allopurinol therapy and 2) Placebo.

Patients will receive: 3 month study drug (either allopurinol or placebo), with assessment of serum uric acid levels and vascular function.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Individuals with moderate chronic kidney disease (CKD stage III) with estimated glomerular filtration rates between 30-60 mL/min/ 1.73m2
* Elevated uric acid levels
* Age range: more than 18 years old
* Ability to give informed consent
* Albumin \> 3.0 g/dL
* BMI \< 40 kg/m2

Exclusion Criteria:

* Life expectancy \< 1.0 years
* Expected to undergo living related kidney transplant in 6 months
* Pregnant, breast feeding, or unwilling to use adequate birth control
* History of severe liver disease
* History of severe congestive heart failure
* History of hospitalizations within 3 months
* Active infection, on antibiotics
* History of Warfarin Use or other medications that are contraindicated with allopurinol
* Uncontrolled hypertension
* History of acute gout on Allopurinol
* History of adverse reaction to Allopurinol
* Immunosuppressive therapy within the last 1 yr
```

## Arms

- **Control** (PLACEBO_COMPARATOR) — Patients who are randomized to this group will received placebo tablets. Placebo tables do not contain an active ingredient. This group will be used as a baseline group to compare the effects of lowering uric acid on vascular function.
- **Allopurinol** (ACTIVE_COMPARATOR) — Patients who are randomized to this group will receive allopurinol tablets. Allopurinol is a medicine that lowers uric acid levels. The effects of lowering uric acid on vascular function outcomes will be assessed and compared to the control group.

## Interventions

- **Allopurinol** (DRUG) — Xanthine oxidase inhibitor- effective at lowering uric acid levels.
- **Placebo** (OTHER) — Placebo tablets with no active ingredient

## Primary Outcomes

- **Change in Endothelial Dependent Dilation From Baseline to Week 12** _(time frame: Baseline and 12 weeks)_ — Change in Endothelial Dependent Dilation measured by Flow Mediated Dilation at baseline and week 12

## Secondary Outcomes

- **Change in C-reactive Protein From Baseline to Week 12** _(time frame: Baseline and 12 weeks)_
- **Change in Serum Interleukin-6 From Baseline to Week 12** _(time frame: Baseline and 12 weeks)_
- **Change in Monocyte Chemotactic Protein-1 From Baseline to Week 12** _(time frame: Baseline and 12 weeks)_
- **Change in Oxidized Low Density Lipoprotein From Baseline to Week 12** _(time frame: Baseline and 12 weeks)_

## Locations (1)

- University of Colorado at Denver, Aurora, Colorado, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of colorado at denver|aurora|colorado|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01228903.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01228903*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*